BioSpace News Archive

Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.

The Comisión Federal para la Protección contra Riesgos Sanitarios has approved CTL Amedica Corporation’s MONET™ Anterior Cervical Interbody Fusion System for use in Mexico.

ASC Therapeutics today announced that the first patient has been dosed in the company’s Phase I/IIa clinical trial of the lead candidate, ASC618, at the Arkansas Children’s Hospital.

ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System.

Co-Diagnostics, Inc. announced today that Co-Diagnostics will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023.

ShiraTronics, Inc. announced the initiation of its groundbreaking RELIEV-CM pilot study in Australia, marking the world’s first seven patients’ successful completion of trial phase procedures for their Chronic Migraine Therapy System.

The global drug discovery services market size was exhibited at USD 19.37 billion in 2022 and it is expected to hit around USD 75.68 billion by 2032, growing at a CAGR of 14.6% during the forecast period from 2023 to 2032.

Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.